SCHEMBL31677892

SCHEMBL31677892

CCc1nc2n(CC(=O)Nc3ccc(C(F)(F)F)cc3)c(C)c(Br)n2c(=O)c1C

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.43
▸ AKR1B1 P15121 1/20 0.41
▸ TRPA1 O75762 1/20 0.40
▸ FPR2 P25090 2/20 0.39
▸ FPR1 P21462 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ LMNA P02545 2/20 0.38
▸ PTGDR2 Q9Y5Y4 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KCNJ5 P48544 1/20 0.38
▸ KCNJ3 P48549 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31678822 0.88 KDM4E (0.44) KDM4EAKR1B1TRPA1FPR2FPR1
SCHEMBL31678102 0.85 KDM4E (0.40) KDM4EAKR1B1TRPA1FPR2FPR1
SCHEMBL31677885 0.83 KDM4E (0.43) KDM4EAKR1B1TRPA1FPR2FPR1
SCHEMBL31677806 0.83 AKR1B1 (0.40) KDM4EAKR1B1TRPA1FPR2MAPT
SCHEMBL31678064 0.82 KDM4E (0.38) KDM4EAKR1B1TRPA1FPR2FPR1
SCHEMBL31678236 0.81 KDM4E (0.39) KDM4EAKR1B1TRPA1FPR2FPR1
SCHEMBL31653799 0.79 ALDH1A1 (0.45) KDM4EAKR1B1TRPA1MAPTLMNA
SCHEMBL31664556 0.77 AKR1B1 (0.45) KDM4EAKR1B1TRPA1FPR2FPR1
SCHEMBL31677760 0.77 KDM4E (0.43) KDM4EAKR1B1TRPA1FPR2FPR1
SCHEMBL31678760 0.77 KDM4E (0.43) KDM4EAKR1B1TRPA1FPR2FPR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270218-A1 IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES AS WRN INHIBITORS INCYTE CORPORATION (US) 2025-08-28 — — US disclosed
US-20250270217-A1 IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES HAVING A COVALENT WARHEAD AT THE 3-POSITION AS WRN INHIBITORS INCYTE CORPORATION (US) 2025-08-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250270217-A1 IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES HAVING A COVALENT WARHEAD AT THE 3-POSITION AS WRN INHIBITORS WRN, RECQL, BLM KDM4E 2390/4885AKR1B1 2548/4885TRPA1 3835/4885
US-20250270218-A1 IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES AS WRN INHIBITORS WRN, RECQL, BLM KDM4E 3187/4885AKR1B1 2350/4885TRPA1 4243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback